• Arnold C Paulino, Anita Mahajan, Rong Ye, David R Grosshans, Fatih Okcu M M Texas Children's Cancer Center and Baylor College of Medicine, Houston, USA., Jack Su, Mary Frances McAleer, Susan McGovern, Victor A Mangona, and Murali Chintagumpala.
• Department of Radiation Oncology, MD Anderson Cancer Center, Houston, USA. Electronic address: apaulino@mdanderson.org.
• Radiother Oncol. 2018 Jul 1; 128 (1): 128-132.

PurposeTo compare ototoxicity rates between medulloblastoma patients treated with protons vs. photons.Materials And MethodsThe study included 84 children diagnosed with medulloblastoma treated with either passively scattered protons (n = 38) or photons (n = 46). Patients underwent maximal safe resection followed by craniospinal irradiation, posterior fossa and/or tumor bed boost and chemotherapy according to one of 3 multi-institutional trials. Median audiogram follow-up was 56 months for protons and 66 months for photons.ResultsMean cochlear dose (Dmc) was lower in patients treated with protons for both standard (p < 0.0001) and high-risk disease (p < 0.001). Grade 3 and 4 ototoxicity was seen in 7 of 75 (9.3%) and 9 of 91 (9.9%) ears (Brock, p = 0.91), 13 of 75 (17.3%) and 19 of 91 (20.9%) ears (POG, p = 0.56), and 15 of 75 (20.0%) and 21 of 91 (23.1%) ears (SIOP Boston, p = 0.63) with protons and photons respectively.ConclusionsWhile cochlear doses were lower in the proton group, patients treated with either protons or photons had similar Grade 3 and 4 ototoxicity rates.Copyright © 2018 Elsevier B.V. All rights reserved.

34 keywords...

hide…